Taysha draws bullish view at Piper Sandler on lead asset [Seeking Alpha]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Seeking Alpha
the potential of biotech's lead asset, TSHA-102, targeted at the rare neurodevelopmental disorder Rett syndrome. Issuing a $9 price target on the stock, Piper argued that TSHA-102, a gene transfer therapy, represents a more than $900M revenue opportunity as Rett syndrome remains largely an unmet medical need despite the availability of an FDA-approved treatment. In March, the U.S. approved Acadia Pharmaceuticals ( ACAD ) Rett syndrome therapy Daybue for those two years and older. Despite its "moderate efficacy" and uncertain gastrointestinal tolerability profile, Daybue, also known as trofinetide, is on track to generate roughly 500M in FY24 sales, "demonstrating to us the profound unmet need in Rett syndrome," analyst Christopher Raymond added. With Taysha's ( TSHA ) market capitalization at $500M, "we believe the stock has only just started to reflect this potential," Raymond wrote, noting the company's upcoming Phase 1/2 readouts for TSHA-102 in the months ahead. Recommen
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipBusiness Wire
- ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024Business Wire
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 2/27/24 - Miss
ACAD
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/15/24 - Form 3
- ACAD's page on the SEC website